The expanding pharmacopoeia for bipolar disorder

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 173-188

  Mitchell, Philip B ^a   Malhi, Gin S ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Carbamazepine; Lamotrigine; Mood stabilizers; Olanzapine; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLOZAPINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; MARCKS PROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; PROTEIN KINASE C; RISPERIDONE; TAMOXIFEN CITRATE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FETOTOXICITY; HUMAN; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MOOD; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRIORITY JOURNAL; RASH; REVIEW; STEVENS JOHNSON SYNDROME;

ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; PHARMACOPOEIAS; UNITED STATES;

EID: 0036183555     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.103933     Document Type: Review

References (74)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States
2. Historical perspectives and natural history of bipolar disorder
3. 12-Month outcome of patients with bipolar disorder following hospitalisation for a manic or mixed episode
4. Neuroplasticity and cellular resilience in mood disorders
5. Forty years of lithium treatment
6. Methodological considerations for the development of new treatments for bipolar disorder
7. The impact of the discovery of lithium on psychiatric thought and practice in the USA and Europe
8. Carbamazepine in manic-depressive illness: A new treatment
9. Correlates of antimanic response to carbamazepine
10. Carbamazepine in manic syndromes. A controlled double-blind study
11. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses
12. Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol
13. Carbamazepine versus lithium in mania: A double-blind study
14. Carbamazepine vs lithium in the treatment and prophylaxis of mania
15. Carbamazepine compared with lithium in the treatment of mania
16. Use of carbamazepine in acute psychosis: A controlled study
17. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study
18. Lithium compared to valproic acid and carbamazepine in the treatment of mania: A statistical meta-analysis
19. Antidepressant effects of carbamazepine
20. Treatment of bipolar depression with carbamazepine: Results of an open study
21. Carbamazepine and its - 10,11-epoxide metabolite in plasma and CSF
22. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness
23. The effect of carbamazepine and lithium on remission from affective illness
24. The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients
25. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder
26. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder
27. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: A meta-analysis
28. Lithium versus carbamazepine in the maintenance treatment of bipotar disorders: A randomized study
29. Adding lithium carbonate to carbamazepine: Antimanic efficacy in treatment-resistant mania
30. The addition of lithium to carbamazepine
31. Valproate in the treatment of acute mania: A placebo-controlled study
32. A double-blind comparison of valproate and lithium in the treatment of acute mania
33. Efficacy of divalproex vs lithium and placebo in the treatment of mania
34. Depression during mania: Treatment response to lithium or divalproex
35. Mania: Differential effects of previous depressive and manic episodes on response to treatment
36. Relation to serum valproate concentration to response in mania
37. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: A prospective, randomized, double-blind, placebo-controlled, multicentre study
38. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania
39. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients
40. Intravenous valproate loading in acutely manic and depressed bipolar I patients
41. Carbamazepine and valproate monotherapy: Feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder
42. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression
43. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder
44. Comparative study of valpromide versus lithium as prophylactic treatment in affective disorders
45. Rapid cycling bipolar disorder and its treatment with valproate
46. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder
47. Medication status and polycystic ovary syndrome in women with bipolar disorder a preliminary report
48. Serum valproate levels in six breastfeeding mother-infant pairs
49. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder
50. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder
51. Lamotrigine compared with lithium in mania: A double-blind randomized controlled trial
52. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression
53. Lamotrigine for the treatment of bipolar disorder: A clinical case series
54. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder
55. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders
56. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy
57. Use of topiramate, a new anti-epileptic as a mood stabilizer
58. Open-label adjunctive topiramate in the treatment of bipolar disorders
59. Advances in the treatment of manic and related disorders: A reappraisal
60. Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: Review of the empirical literature
61. Clozapine for treatment of refractory mania
62. Olanzapine versus placebo in the treatment of acute mania
63. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study
64. Long-term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study
65. Risperidone compared with both lithium and haloperidol in mania: A double-blind randomized controlled trial
66. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders
67. Verapamil for the treatment of acute mania: A double-blind, placebo-controlled trial
68. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation
69. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness
70. Omega 3 fatty acids in bipolar disorder
71. Choline in the treatment of rapid-cycling bipolar disorder
72. Donepezil in treatment-resistant bipolar disorder
73. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania